Introduction to feldene and piroxicam
Feldene is a brand-name prescription medication containing the active ingredient piroxicam, a nonsteroidal anti-inflammatory drug (NSAID) belonging to the oxicam class. First approved by the United States Food and Drug Administration in 1982, piroxicam was a significant addition to the NSAID options due to its unique pharmacokinetic profile characterized by a long elimination half-life that allows for once-daily dosing in most patients. Feldene is used primarily for the management of pain and inflammation associated with various arthritic conditions including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for acute musculoskeletal disorders and other inflammatory conditions. The medication is available in several formulations including capsules, tablets, and injectable solutions, providing flexibility in administration for different clinical situations.
Piroxicam is distinguished from many other NSAIDs by its exceptionally long half-life of approximately 50 hours in healthy adults, which allows for convenient once-daily dosing while maintaining therapeutic drug concentrations throughout the day. This extended half-life is due to the extensive enterohepatic recirculation of piroxicam, in which the drug is excreted in the bile and then reabsorbed from the intestine, prolonging its presence in the body. While this pharmacokinetic property offers the advantage of simplified dosing, it also means that adverse effects may persist longer after discontinuation compared to shorter-acting NSAIDs, and that recovery from toxicity may be slower. Patients and healthcare providers must be aware of these characteristics when using Feldene for acute or chronic conditions.
The clinical use of Feldene has been supported by extensive research spanning more than three decades. Numerous clinical trials have demonstrated that piroxicam is effective in reducing pain and inflammation in patients with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, with efficacy comparable to that of other NSAIDs including indomethacin, naproxen, and diclofenac. The once-daily dosing regimen of Feldene offers advantages in terms of patient convenience and compliance, particularly for patients who require long-term NSAID therapy for chronic arthritic conditions. However, the long half-life also means that adverse effects may be more prolonged if they occur, and careful patient selection and monitoring are essential for safe use.
The safety profile of Feldene has been the subject of ongoing evaluation and regulatory attention. Like all NSAIDs, piroxicam carries risks of gastrointestinal, cardiovascular, renal, and hepatic adverse effects, and the long half-life means that these risks may be amplified compared to shorter-acting NSAIDs in some settings. Regulatory authorities in several countries have issued specific warnings about the gastrointestinal risks of piroxicam and have recommended that it be used only after other NSAIDs have been tried and found inadequate, particularly in elderly patients. Despite these concerns, Feldene remains an effective therapeutic option for appropriately selected patients when used at the lowest effective dose for the shortest possible duration under appropriate medical supervision.
For patients who require Feldene for their medical condition, access through various pharmacy channels including online platforms such as Happy Family Store can facilitate treatment. However, it is essential that patients obtain Feldene only from licensed and reputable sources to ensure product quality and authenticity, and that they use the medication under the guidance of a qualified healthcare provider who can assess the risks and benefits for their individual situation. Self-medication with prescription NSAIDs is not recommended, and patients should always consult with a healthcare professional before starting or modifying any NSAID therapy.
Medical uses and indications
The primary indication for Feldene is the management of osteoarthritis, a degenerative joint disease that affects millions of people worldwide. Osteoarthritis results from the progressive breakdown of articular cartilage within synovial joints, leading to pain, stiffness, swelling, and functional limitation. Feldene helps manage these symptoms by reducing inflammation within the affected joints, improving patients’ mobility and quality of life. Clinical studies have shown that piroxicam at doses of 10 to 20 mg once daily is effective in reducing osteoarthritis pain and improving physical function, with effects that are comparable to those of other NSAIDs used for this condition. The once-daily dosing of Feldene is particularly advantageous for patients with osteoarthritis who require long-term therapy, as it simplifies the treatment regimen and may improve adherence.
Rheumatoid arthritis is another major indication for Feldene therapy. Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by symmetric polyarticular inflammation of the synovial joints, leading to pain, swelling, stiffness, and progressive joint destruction if not adequately controlled. Feldene provides symptomatic relief from the inflammatory manifestations of rheumatoid arthritis, reducing joint pain and swelling, decreasing morning stiffness, and improving overall functional capacity. As with other NSAIDs, piroxicam does not modify the underlying disease process in rheumatoid arthritis and should be used as adjunctive therapy alongside disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, or biologic agents. The recommended dose of Feldene for rheumatoid arthritis is 20 mg once daily, which may be reduced to 10 mg once daily for maintenance therapy once symptoms are controlled.
Ankylosing spondylitis, a chronic inflammatory disease primarily affecting the axial skeleton, responds well to Feldene therapy. Patients with ankylosing spondylitis experience chronic back pain, morning stiffness, and progressive spinal stiffness that can lead to significant disability if not managed appropriately. Feldene reduces spinal inflammation and pain, alleviates morning stiffness, and improves spinal mobility, allowing patients to participate more effectively in physical therapy and exercise programs. The long half-life of piroxicam is particularly advantageous for ankylosing spondylitis, as the sustained drug levels provide consistent symptom control throughout the day and night, reducing the breakthrough pain and stiffness that can occur with shorter-acting NSAIDs before the next dose is due.
Acute musculoskeletal disorders including acute tendinitis, bursitis, and acute gouty arthritis may also be treated with Feldene. For acute tendinitis and bursitis, piroxicam reduces local inflammation and pain, promoting faster recovery and return to normal activities. For acute gout flares, Feldene can be used to control the intense pain and inflammation, typically at a dose of 20 mg once daily for the duration of the attack. The long half-life of piroxicam means that therapeutic concentrations are maintained consistently throughout the treatment period, which may be advantageous for managing the severe and persistent pain of acute gout. However, the prolonged duration of action also means that any adverse effects that develop may persist longer, and careful patient monitoring is required.
Primary dysmenorrhea is another indication for which Feldene may be prescribed. The medication reduces prostaglandin-mediated uterine contractions and inflammation associated with menstruation, providing relief from painful menstrual cramps. The once-daily dosing of Feldene for dysmenorrhea is convenient and may improve compliance compared to NSAIDs that require multiple daily doses. The recommended dose for dysmenorrhea is 20 mg once daily, taken at the onset of symptoms and continued for the first few days of menstruation as needed. As with other NSAIDs, piroxicam should be used at the lowest effective dose for the shortest duration necessary for this indication.
Feldene has also been used for other inflammatory conditions including psoriatic arthritis, Reiter syndrome, and other seronegative spondyloarthropathies. In these conditions, piroxicam provides symptomatic relief from joint pain and inflammation, improving patients’ quality of life and functional capacity. The use of Feldene for these conditions is based on clinical experience and extrapolation from its efficacy in other inflammatory arthritides, rather than on large-scale clinical trials specific to each condition. Patients with these conditions should be managed by a rheumatologist or other specialist who can determine the most appropriate treatment approach, which may include Feldene as part of a comprehensive management plan.
Mechanism of action
The mechanism of action of piroxicam, the active ingredient in Feldene, involves inhibition of cyclooxygenase (COX) enzymes, specifically the COX-1 and COX-2 isoforms that catalyze the conversion of arachidonic acid to prostaglandin H2, the precursor of various prostaglandins and thromboxanes. Piroxicam is a non-selective NSAID, meaning it inhibits both COX-1 and COX-2 with approximately equal potency. This balanced inhibition profile provides effective anti-inflammatory and analgesic effects through reduction of COX-2-derived pro-inflammatory prostaglandins, and carries the risk of gastrointestinal adverse effects through inhibition of COX-1-derived protective prostaglandins in the gastric mucosa. The non-selective nature of piroxicam is similar to that of other traditional NSAIDs such as ibuprofen, naproxen, and indomethacin.
The binding of piroxicam to COX enzymes involves a unique kinetic profile that differs from that of many other NSAIDs. Piroxicam binds to both COX-1 and COX-2 in a time-dependent manner, with the binding being slowly reversible, which contributes to its long duration of action. The dissociation half-life of piroxicam from COX enzymes is longer than that of most other NSAIDs, meaning that once bound, the drug remains associated with the enzyme for an extended period, providing sustained inhibition of prostaglandin synthesis. This prolonged enzyme inhibition, combined with the long plasma half-life of piroxicam, results in sustained therapeutic effects that support once-daily dosing and provide consistent symptom control throughout the dosing interval.
The anti-inflammatory effects of piroxicam are mediated primarily through reduced production of prostaglandin E2 (PGE2) and other inflammatory prostaglandins at sites of inflammation. PGE2 is a potent vasodilator that promotes the redness and heat of inflammation, enhances the effects of other inflammatory mediators that increase vascular permeability and cause swelling, and sensitizes peripheral nociceptors to pain-producing stimuli. By reducing PGE2 production, piroxicam decreases vasodilation and edema at inflammatory sites, attenuates the pain response, and provides symptomatic relief from inflammation. The reduction in prostaglandin production also contributes to the antipyretic (fever-reducing) effects of piroxicam, as PGE2 acts on the hypothalamus to raise the body’s temperature set point during febrile illness.
Beyond COX inhibition, piroxicam may have additional mechanisms that contribute to its therapeutic profile. Studies have suggested that piroxicam can inhibit the activation and function of neutrophils, which are key cellular mediators of the inflammatory response. Piroxicam may also affect the production of reactive oxygen species and the release of lysosomal enzymes from inflammatory cells, contributing to its anti-inflammatory effects independent of COX inhibition. Also, piroxicam has been shown to inhibit the production of certain cytokines, including interleukin-1 and tumor necrosis factor-alpha, which are key mediators of the inflammatory cascade in arthritic conditions. The clinical significance of these additional mechanisms in the overall therapeutic effect of piroxicam is not fully established but may contribute to its efficacy in inflammatory conditions.
The pharmacokinetic profile of piroxicam is unique among NSAIDs and is the basis for its once-daily dosing regimen. After oral administration, piroxicam is well absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 3 to 5 hours. The oral bioavailability of piroxicam is approximately 100 percent, indicating complete absorption, and food does not affect the extent or rate of absorption. Piroxicam is bound to plasma proteins (approximately 99 percent), primarily albumin, resulting in a small volume of distribution of approximately 0.15 L/kg. The most distinctive pharmacokinetic feature of piroxicam is its long elimination half-life of approximately 50 hours (range 30 to 86 hours), which is due to its extensive enterohepatic recirculation and slow metabolic clearance.
The metabolism of piroxicam occurs primarily in the liver through cytochrome P450-mediated hydroxylation, primarily by CYP2C9, followed by conjugation with glucuronic acid. The major metabolite, 5-hydroxypiroxicam, has minimal pharmacological activity. Piroxicam and its metabolites are eliminated through both renal and biliary routes, with approximately two-thirds of the dose excreted in the urine and one-third in the feces. The long half-life of piroxicam means that steady-state plasma concentrations are not achieved until approximately 7 to 12 days after the start of therapy, which has implications for the time course of both therapeutic effects and adverse effects. When therapy is discontinued, it takes approximately 10 to 14 days for the drug to be completely eliminated from the body, which means that adverse effects may persist for some time after the last dose.
Dosage and administration
The recommended dose of Feldene for most indications is 20 mg taken once daily. For some patients, particularly those with milder symptoms or those who are at increased risk of adverse effects, a starting dose of 10 mg once daily may be appropriate, with the dose increased to 20 mg once daily if adequate symptom control is not achieved. The maximum recommended daily dose of Feldene is 20 mg, and doses above this level do not provide additional therapeutic benefit but increase the risk of adverse effects. For acute musculoskeletal conditions, treatment with Feldene is typically limited to 7 to 14 days, while chronic conditions such as osteoarthritis and rheumatoid arthritis may require longer-term therapy under appropriate medical supervision.
Feldene capsules or tablets should be taken with a full glass of water and should be swallowed whole without crushing or chewing. Taking Feldene with food or milk may help reduce gastrointestinal irritation, although food does not affect the absorption of the medication. Patients should be advised to take Feldene at approximately the same time each day to maintain consistent drug levels and to help establish a routine that improves compliance. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped and the regular schedule resumed. Patients should not take a double dose to make up for a missed dose.
For elderly patients, particular caution is required when using Feldene due to the increased risk of adverse effects and the long half-life of piroxicam. Elderly patients are more likely to have impaired renal and hepatic function, reduced serum albumin levels leading to altered drug binding, and concurrent medical conditions and medications that increase the risk of NSAID-related complications. The manufacturer recommends that the lowest effective dose of Feldene be used in elderly patients, and that treatment be initiated at 10 mg once daily rather than 20 mg once daily. Close monitoring for adverse effects, particularly gastrointestinal bleeding, renal impairment, and cardiovascular events, is essential in elderly patients receiving Feldene.
Special dosing considerations apply to patients with renal or hepatic impairment. Piroxicam should be used with caution in patients with mild to moderate renal impairment, and it is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min). Patients with hepatic impairment may have altered metabolism of piroxicam and should be monitored closely. The dose of Feldene may need to be reduced in patients with significant hepatic impairment, and the medication should be avoided in patients with active liver disease or elevated liver enzymes. Baseline and periodic monitoring of renal function and liver enzymes is recommended for patients receiving long-term Feldene therapy.
The use of Feldene in pediatric populations has not been well studied, and the medication is not recommended for use in children under 14 years of age except under special circumstances and under the supervision of a pediatric specialist. The long half-life of piroxicam is a particular concern in children, who may be more susceptible to the adverse effects of NSAIDs and in whom the prolonged drug elimination time could complicate management of toxicity.
Adverse effects and safety profile
Gastrointestinal adverse effects are among the most common and significant side effects of Feldene therapy, consistent with its non-selective COX inhibition. Common gastrointestinal effects include dyspepsia (indigestion), abdominal pain, nausea, vomiting, diarrhea, constipation, flatulence, and heartburn. The risk of more serious gastrointestinal events including gastric or duodenal ulcers, upper gastrointestinal bleeding, perforation, and obstruction is significant with piroxicam, particularly in elderly patients and those with other risk factors. The long half-life of piroxicam means that if gastrointestinal injury occurs, it may be more severe and prolonged compared to shorter-acting NSAIDs, as the drug continues to inhibit protective gastric prostaglandins for an extended period. Regulatory authorities in several countries have issued specific warnings about the gastrointestinal risks of piroxicam and recommend that it be reserved for patients who have not responded adequately to other NSAIDs.
Cardiovascular adverse effects associated with Feldene use include hypertension, fluid retention, peripheral edema, and increased risk of serious cardiovascular events including myocardial infarction, stroke, and heart failure exacerbation. The risk of cardiovascular events with piroxicam is thought to be similar to that of other non-selective NSAIDs, although some studies have suggested that the risk may be higher with piroxicam compared to some other NSAIDs due to its long half-life and sustained COX inhibition. Patients with established cardiovascular disease, including coronary artery disease, cerebrovascular disease, and heart failure, should use Feldene with caution, and the medication should be avoided when possible in patients with recent myocardial infarction or stroke. Blood pressure should be monitored regularly in patients receiving Feldene, and the medication should be discontinued if significant hypertension develops.
Renal adverse effects can occur with Feldene use, particularly in patients with preexisting renal impairment, heart failure, cirrhosis, or volume depletion. NSAIDs including piroxicam can reduce renal blood flow and glomerular filtration rate by inhibiting prostaglandin-dependent renal vasodilation, leading to fluid retention, edema, hypertension, and in some cases, acute kidney injury. The long half-life of piroxicam means that if renal impairment develops, it may be more prolonged compared to shorter-acting NSAIDs, and recovery may be slower. Electrolyte abnormalities including hyperkalemia may occur, particularly in patients with renal impairment or those taking potassium-sparing diuretics, ACE inhibitors, or angiotensin receptor blockers. Renal function should be monitored periodically in patients at risk, and Feldene should be discontinued if significant renal impairment develops.
Hepatic adverse effects associated with Feldene include elevations in liver enzymes (transaminases), which occur in a small percentage of patients and are generally asymptomatic and reversible. Clinically significant hepatic injury, including jaundice, hepatitis, and liver failure, is rare but has been reported with piroxicam and other NSAIDs. The prolonged half-life of piroxicam means that if hepatic injury develops, the drug will continue to exert effects on the liver for an extended period after discontinuation, potentially worsening the clinical course. Patients who develop symptoms of hepatic injury, including fatigue, loss of appetite, nausea, abdominal pain, dark urine, or jaundice, should discontinue Feldene and seek medical evaluation. Liver function should be monitored at baseline and periodically during long-term therapy.
Neurological adverse effects include headache, dizziness, drowsiness, and, less commonly, insomnia, nervousness, and depression. These effects are typically mild and dose-related and may resolve with continued use or dose reduction. Patients who experience significant dizziness or drowsiness should avoid driving or operating heavy machinery until the effects subside. Tinnitus (ringing in the ears) may occur at high doses and is usually reversible upon dose reduction or discontinuation. Aseptic meningitis, although rare, has been reported with NSAID use and requires immediate medical evaluation.
Dermatological adverse effects range from mild skin rashes and pruritus to rare but severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Patients who develop a skin rash, blisters, or mucosal lesions should discontinue Feldene and seek medical attention. Photosensitivity reactions may occur, and patients should use sun protection measures during therapy. Hypersensitivity reactions including urticaria, angioedema, and anaphylaxis can occur in susceptible individuals, particularly those with a history of aspirin or NSAID allergy.
Contraindications and precautions
Feldene is contraindicated in patients with known hypersensitivity to piroxicam or any component of its formulation, and in patients who have experienced allergic reactions to aspirin or other NSAIDs. The risk of severe cross-sensitivity reactions among NSAIDs is significant, and patients with a history of NSAID allergy should avoid piroxicam and all other NSAIDs. Feldene is also contraindicated in patients with active peptic ulcer disease or gastrointestinal bleeding, as the medication may exacerbate these conditions. Patients with a history of recurrent peptic ulcer disease or gastrointestinal bleeding should use piroxicam only after careful consideration of the risks and benefits and when alternative therapy is not available.
Cardiovascular contraindications include the use of Feldene for perioperative pain management in patients undergoing coronary artery bypass graft surgery, as NSAIDs have been associated with an increased risk of cardiovascular events in this setting. Feldene should be avoided in patients with severe heart failure (New York Heart Association class III or IV). Uncontrolled hypertension is a relative contraindication. Patients with established cardiovascular disease or significant cardiovascular risk factors should use piroxicam with caution and only when alternative therapy is not available. Given the long half-life of piroxicam and the potential for sustained cardiovascular effects, particular caution is warranted in patients with cardiovascular risk factors.
Renal contraindications include severe renal impairment (creatinine clearance less than 30 mL/min). Feldene should be used with caution in patients with mild to moderate renal impairment, with close monitoring of renal function. The medication should be avoided in patients with volume depletion. Patients with hepatic impairment should use Feldene with caution, and the medication is contraindicated in patients with active liver disease or elevated liver enzymes.
Pregnancy and lactation considerations impose important restrictions on Feldene use. The medication is classified as pregnancy category C during the first and second trimesters and category D during the third trimester. Piroxicam should be avoided during pregnancy, particularly in the third trimester, because NSAIDs can cause premature closure of the ductus arteriosus in the fetus and may impair fetal renal function. The long half-life of piroxicam is a particular concern in pregnancy, as the drug will persist in the maternal and fetal circulation for an extended period, potentially prolonging fetal exposure. Women who are trying to conceive should avoid piroxicam due to potential effects on fertility. The safety of piroxicam during breastfeeding has not been established, and the medication should be used with caution in nursing mothers.
Clinical studies and efficacy
The efficacy of Feldene in osteoarthritis has been established through numerous clinical trials comparing piroxicam to placebo and other NSAIDs. In these studies, piroxicam at doses of 10 to 20 mg once daily demonstrated significant improvements in pain intensity, physical function, and patient global assessment compared to placebo. The efficacy of piroxicam was comparable to that of other NSAIDs including naproxen, indomethacin, and diclofenac in head-to-head comparisons. Once-daily dosing with piroxicam was found to provide consistent symptom control throughout the 24-hour dosing interval, with many patients reporting sustained pain relief and improved morning stiffness compared to shorter-acting NSAIDs. Long-term studies have confirmed the sustained efficacy of piroxicam in osteoarthritis over periods of up to 12 months.
In rheumatoid arthritis, piroxicam at doses of 20 mg once daily has been shown to be superior to placebo and comparable to other NSAIDs in reducing joint pain, swelling, and morning stiffness. The American College of Rheumatology response criteria and other validated measures of disease activity showed clinically meaningful improvements in piroxicam-treated patients. As with other NSAIDs, piroxicam does not slow the radiographic progression of joint damage in rheumatoid arthritis and should be used as adjunctive therapy alongside DMARDs. The once-daily dosing of piroxicam may improve compliance in patients with rheumatoid arthritis who are already taking multiple medications for their disease.
The long-term safety of piroxicam has been evaluated in observational studies and post-marketing surveillance databases. While piroxicam is effective for symptomatic relief in arthritic conditions, its long-term use is limited by concerns about gastrointestinal and cardiovascular safety. The risk of serious gastrointestinal events with piroxicam appears to be higher than that with some other NSAIDs, particularly in elderly patients and those with other risk factors. These safety concerns have led to the recommendation that piroxicam be used only when other NSAIDs have been tried and found inadequate, and that it be used at the lowest effective dose for the shortest possible duration.
Frequently asked questions
Is Feldene available over the counter? In most countries, Feldene (piroxicam) is available only with a prescription from a licensed healthcare provider. Due to its long half-life and significant adverse effect profile, medical supervision is required to ensure appropriate use and monitoring. Online pharmacies such as Happy Family Store may offer Feldene through various channels, but patients should always consult with a healthcare provider before using this medication.
Why is Feldene dosed once daily when other NSAIDs are taken multiple times daily? Feldene has a uniquely long elimination half-life of approximately 50 hours, which allows it to be taken once daily while maintaining therapeutic drug concentrations throughout the dosing interval. This extended half-life results from extensive enterohepatic recirculation and slow metabolic clearance. The once-daily dosing regimen offers convenience advantages and means that adverse effects may persist longer if they occur.
Is piroxicam more effective than other NSAIDs? The efficacy of piroxicam is comparable to that of other NSAIDs such as naproxen, diclofenac, and indomethacin for most indications. Its primary advantage is the convenience of once-daily dosing, which may improve patient compliance. However, the long half-life also carries potential disadvantages, including prolonged adverse effects and slower recovery if toxicity occurs. The choice between piroxicam and other NSAIDs should be based on individual patient factors and risk assessment.
Can Feldene be taken with other pain medications? Feldene should not be taken with other NSAIDs, including over-the-counter medications containing ibuprofen, naproxen, or aspirin, as this increases the risk of gastrointestinal and renal adverse effects without providing additional therapeutic benefit. Acetaminophen (paracetamol) may be taken concurrently with Feldene for additional pain relief if needed, but patients should consult their healthcare provider before combining any medications.
How long does it take for Feldene to start working? The onset of action of piroxicam is relatively slow compared to shorter-acting NSAIDs, reflecting its pharmacokinetic profile. Some pain relief may be experienced within the first few hours after the first dose, but maximum therapeutic benefit is not achieved until steady-state plasma concentrations are reached, which typically takes 7 to 12 days. Patients should be advised to take Feldene consistently for at least 1 to 2 weeks before evaluating its effectiveness for chronic conditions.
What are the most serious risks associated with Feldene? The most serious risks of Feldene therapy include gastrointestinal bleeding and ulceration, cardiovascular events including heart attack and stroke, renal impairment, and hepatotoxicity. The risk of these events is increased in elderly patients, those with preexisting medical conditions, and those taking concurrent medications that interact with NSAIDs. The long half-life of piroxicam means that these risks may be amplified compared to shorter-acting NSAIDs. Patients should be monitored closely for signs of these complications, and the medication should be discontinued if they develop.
Can I drink alcohol while taking Feldene? Alcohol consumption should be limited or avoided while taking Feldene, as alcohol can increase the risk of gastrointestinal irritation and bleeding. The combination of piroxicam with alcohol is particularly concerning due to the sustained gastrointestinal effects of the medication. Patients who choose to drink alcohol should do so in moderation and should be aware of potential symptoms of gastrointestinal bleeding.
Is Feldene safe for elderly patients? Elderly patients are at increased risk of adverse effects from Feldene, including gastrointestinal bleeding, cardiovascular events, and renal impairment, and the long half-life of piroxicam amplifies these concerns. The manufacturer recommends that the lowest effective dose (typically starting at 10 mg once daily) be used in elderly patients, and that alternative NSAIDs be considered when possible. Close monitoring for adverse effects is essential in elderly patients receiving Feldene.
Can Feldene be used during pregnancy? No, Feldene should be avoided during pregnancy, particularly in the third trimester, because NSAIDs can cause premature closure of the ductus arteriosus in the fetus and impair fetal renal function. The long half-life of piroxicam is a particular concern in pregnancy, as fetal exposure may be prolonged. Women who are trying to conceive should also avoid piroxicam due to potential effects on ovulation and fertility.
What should I do if I experience side effects from Feldene? Patients who experience any side effects while taking Feldene should contact their healthcare provider promptly. Mild gastrointestinal symptoms such as heartburn or indigestion may be managed by taking the medication with food, using antacids, or reducing the dose. However, any signs of serious adverse effects, including black or bloody stools, abdominal pain, chest pain, shortness of breath, swelling of the extremities, skin rash, or jaundice, require immediate medical attention and discontinuation of the medication.